Regional Capability of Different Regions Within China

The key parameters that, we believe, are likely to have an influence on the regional capability of biopharmaceutical manufacturing, and hence, were taken into consideration, include:

• Number of CMOs: This parameter takes into account the number of biopharmaceutical CMOs headquartered in a particular geography; during our research, we were able to identify 39 such players that were based in China.
• Number of Clinical Sites: This parameter takes into account the total number of clinical sites located in a particular geography that are conducting trials and enrolling patients for clinical studies; we came across 3,850 clinical sites that were based in China, including Hong Kong and Taiwan.
• Number of Clinical Trials: This parameter takes into account the total number of completed / ongoing / planned clinical trials across different geographical regions. Presently, 1,935 biopharmaceuticals focused clinical trials have been / are being / are planned to be conducted in China, including Hong Kong and Taiwan.
• Number of Patients Enrolled: This parameter takes into account the total number of patients enrolled (1,470,388) in various biopharmaceuticals focused clinical trials that were / are registered in different regions across China, including Hong Kong and Taiwan.
• Number of Manufacturing Facilities: This parameter takes into account the number of biopharmaceuticals manufacturing facilities located in a particular geography; a total of 65 such facilities are located in China.
• Number of API / FDF Manufacturing Facilities: This parameter takes into account the number of API / FDF manufacturing facilities located in a particular region.
• Number of Clinical / Commercial Manufacturing Facilities: This parameter take into account the number of clinical / commercial manufacturing facilities located in a particular region.
• Installed Capacity: This parameter takes into account the installed contract manufacturing capacity (in terms of liters) of service providers in a particular region. The total, annual, installed capacity in China for biopharmaceutical manufacturing is 0.3 million liters.

Eastern China has emerged as the key biopharmaceutical manufacturing hub in China, having the maximum (over 45%) number of biopharmaceutical manufacturing facilities. It is worth noting that 53% of the overall biopharmaceutical capacity installed in China is also contributed by facilities located in eastern China. Further, maximum number of trials are registered in this region. Within this region, most of the biopharmaceuticals focused trials were registered in Shanghai (325), followed by those being conducted in Jiangsu (193) and Zhejiang (151).

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the biopharmaceutical contract manufacturing market in China. Based on various parameters, such as projected growth of the overall biopharmaceutical market in China, cost of goods sold, and direct manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of product (active pharmaceutical ingredients (APIs) and finished dosage formulations (FDFs)), [B] types of expression systems used (mammalian, microbial and others), [C] scale of operation (preclinical, clinical and commercial), and [D] company size (small, mid-sized and large / very large). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Roots Analysis provides market research and consulting in the pharmaceutical industry. Focussed on providing an informed and impartial view on key issues facing the industry, our research is primarily driven by an in-depth analysis.